In December 2019, a cluster of severe pneumonia was observed in China, with the subsequent discovery of a new beta-coronavirus (SARS-CoV-2) as the causative agent. The elicited disease COVID-19 is characterized by fever, dry cough, myalgia, or fatigue and has a favorable outcome in the majority of cases. However, in some patients COVID-19 leads to severe pneumonia and sepsis with subsequent respiratory failure and gastrointestinal, hematological, neurological, and cardiovascular complications. A higher risk of infection is intrinsic to active rheumatic and musculoskeletal diseases (RMD) and the use of biological disease modifying anti-rheumatic drugs (DMARDs). With an increasing number of reports on COVID-19 in RMD patients, we are beginning to appraise their risks. In this review, we summarize the published cases of COVID-19 infections in RMD patients, including patients with inflammatory arthritis and connective tissue diseases as well as anti-phospholipid syndrome and Kawasaki syndrome. Overall, patients with inflammatory arthritis do not seem to be at a higher risk for infection or a severe course of COVID-19. Risk for critical COVID-19 in patients with systemic inflammatory diseases such as SLE or vasculitis might be increased, but this needs further confirmation. Furthermore, we summarize the data on DMARDs used to fight SARS-CoV-2 infection and hyperinflammation.
【저자키워드】 COVID-19, SARS-CoV-2, Hydroxychloroquine, IL-6, systemic lupus erythematosus, rheumatoid arthritis, Kawasaki disease, rheumatic and musculoskeletal disease, 【초록키워드】 Respiratory failure, fatigue, SARS-COV-2 infection, Infection, Sepsis, outcome, China, COVID-19 infection, hyperinflammation, Fever, Patient, Inflammatory arthritis, Cluster, Vasculitis, severe pneumonia, disease, Critical, patients, Kawasaki syndrome, cardiovascular complications, neurological, myalgia, SLE, beta-coronavirus, connective tissue disease, Musculoskeletal, higher risk, dry cough, syndrome, hematological, Course, intrinsic, subsequent, characterized, majority, elicited, anti-rheumatic drug, COVID-19 in patient, systemic inflammatory disease, 【제목키워드】 review, Month,